STOCK TITAN

MeiraGTx (MGTX) Form 4: Giroux Transfers 5k Shares as Gift

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

SEC Form 4 for MeiraGTx Holdings plc (MGTX) discloses that Richard Giroux, the company’s Chief Financial & Operating Officer, gifted 5,000 ordinary shares on 06/30/2025 (transaction code G, price $0). After this transaction, Giroux still owns 877,494 shares directly and 90,152 shares indirectly (5,152 via spouse; 85,000 via Aigle Healthcare Partners III LLC). No derivative positions were added or reduced, and the filing was signed on 07/02/2025. The Rule 10b5-1 checkbox is not marked, indicating the gift was not executed under a preset trading plan. The transaction reduces Giroux’s direct stake by approximately 0.6%, leaving his overall ownership essentially unchanged. There is no indication of operational or financial impact on MeiraGTx arising from this personal transfer.

Positive

  • None.

Negative

  • None.

Insights

TL;DR – Immaterial insider gift; ownership remains high, neutral to valuation.

The Form 4 shows CFO/COO Richard Giroux gifting 5,000 shares—about 0.6 % of his direct holdings. He retains 877,494 shares directly and 90,152 indirectly, signaling continued alignment with shareholders. No derivatives were involved and the transaction was not under a Rule 10b5-1 plan, so timing discretion was fully his. Given the small size relative to his stake and MeiraGTx’s float, the filing is unlikely to affect market perception or liquidity. I view the disclosure as routine record-keeping rather than a signal of confidence or concern.

SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Giroux Richard

(Last) (First) (Middle)
450 EAST 29TH STREET
14TH FLOOR

(Street)
NEW YORK NY 10016

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
MeiraGTx Holdings plc [ MGTX ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
CFO & COO
3. Date of Earliest Transaction (Month/Day/Year)
06/30/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 06/30/2025 G 5,000 D $0 877,494 D
Ordinary Shares 5,152 I By Spouse
Ordinary Shares 85,000 I By Aigle Healthcare Partners III LLC
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
/s/ Richard Giroux 07/02/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did MeiraGTx (MGTX) report on June 30 2025?

CFO & COO Richard Giroux gifted 5,000 ordinary shares at a price of $0.

How many MGTX shares does Richard Giroux own after the transaction?

He holds 877,494 shares directly and 90,152 shares indirectly (via spouse and Aigle Healthcare Partners III LLC).

What does transaction code "G" mean on Form 4?

Code G designates a gift of securities, with no consideration paid.

Was the transaction executed under a Rule 10b5-1 trading plan?

No. The relevant checkbox is not marked, indicating no Rule 10b5-1 plan was used.

What roles does Richard Giroux hold at MeiraGTx?

He serves as the company’s Chief Financial Officer and Chief Operating Officer.
Meiragtx Holdings Plc

NASDAQ:MGTX

MGTX Rankings

MGTX Latest News

MGTX Latest SEC Filings

MGTX Stock Data

562.63M
53.46M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
NEW YORK